Immediate therapeutic opportunities may involve targeting ApoA-V to regulate TG metabolism for stroke prevention, especially in individuals with genetic risk factors, and exploring the role of ApoA-I in amyloid clearance in Alzheimer’s disease. Here, APOA1 is linked to early-onset autosomal dominant Alzheimer disease.